natgillin/translations-raw huggingface dataset:
Samtidig administration af 40 mg esomeprazol medførte en stigning på 13 % i det laveste plasmaniveau af phenytoin hos epilepsipatienter. 
Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients.
Methacrylsyre-ethylacrylat copolymer (1:1) 30 % opløsning Polysorbat 80 
Methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent Polysorbate 80
Der er ingen relevant anvendelse af Nexium Control i den pædiatriske population under 18 år til indikationen ”kortvarig behandling af reflukssymptomer (f.eks. halsbrand og sure opstød)”. 
There is no relevant use of Nexium Control in the paediatric population below 18 years of age for the indication of “short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation)”.
Disse resultater har ingen indvirkning på doseringen af esomeprazol. 
These findings have no implications for the posology of esomeprazole.
pantoprazol, lansoprazol, rabeprazol eller omeprazol) 
lansoprazole, rabeprazole or omeprazole).
Da esomeprazols metabolitter, men ikke modersubstansen udskilles gennem nyrerne, forventes det ikke, at metaboliseringen forandres hos patienter med nedsat nyrefunktion. 
Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.
Resultater fra studier med raske forsøgspersoner har vist en farmakokinetisk (PK)/farmakodynamisk (PD) interaktion mellem clopidogrel (300 mg loading-dosis/75 mg daglig vedligeholdelsesdosis) og esomeprazol (40 mg oralt dagligt), hvilket resulterede i nedsat eksponering for den aktive metabolit af clopidogrel med et gennemsnit på 40 % og resulterede i mindsket maksimal hæmning af (ADPinduceret) blodpladeaggregering på gennemsnitligt 14 %. 
Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.
Nexium Control fås i pakningsstørrelser med 7 og 14 enterotabletter i blisterpakninger. 
Nexium Control is available in pack sizes of 7 and 14 gastro-resistant tablets in blisters.
Det er påvist, at esomeprazol 20 mg effektivt behandler hyppig halsbrand hos forsøgspersoner, som har fået en dosis daglig i 2 uger. 
Esomeprazole 20 mg has been demonstrated to effectively treat frequent heartburn in subjects receiving one dose per 24 hours over 2 weeks.
• Du er over 55 år og har nye eller nyligt forandrede reflukssymptomer. 
• You are over 55 and have new or recently changed reflux symptoms.
Esomeprazol må ikke anvendes under amning. 
Esomeprazole should not be used during breast-feeding.
Behandling med PPI'er kan derfor forårsage en let forøget risiko for gastrointestinale infektioner såsom Salmonella og Campylobacter og hos indlagte patienter muligvis også Clostridium difficile. 
Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile.
• Ophidset sindstilstand, forvirring eller depression 
• Feeling agitated, confused or depressed.
Kapslerne må ikke synkes hele. 
The capsules should be swallowed whole.
• Læg tabletten i et glas vand uden brus. 
• Put the tablet in a glass of still (non-fizzy) water.
Tag altid dette lægemiddel nøjagtigt som beskrevet i denne indlægsseddel eller efter lægens eller apotekspersonalets anvisning. 
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you.
Investigatorernes vurdering af ophør af halsbrand var i overensstemmelse med forsøgspersonernes vurderinger og viste statistisk signifikant forskel mellem esomeprazol (34,7 - 41,8 %) og placebo (8,0 - 11,4 %). 
The investigators' assessments of heartburn resolution were consistent with the subjects' assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%).
Tag ikke Nexium Control 
Do not take Nexium Control
En lyserød, aflang, bikonveks, filmovertrukken enterotablet på 14 mm x 7 mm mærket med ”20 mG” på den ene side og ”A/EH” på den anden side. 
A light pink, oblong, biconvex, film-coated, gastro-resistant tablet of 14 mm x 7 mm engraved with ‘20 mG' on one side and ‘A/EH' on the other side.
• Alvorlige nyreproblemer 
• Severe kidney problems
Ved samtidig administration med PPI'er er det hos nogle patienter rapporteret en stigning i methotrexatniveauerne. 
When given together with PPIs, methotrexate levels have been reported to increase in some patients.
En dosis på 20 mg esomeprazol bør ikke overskrides. 
Esomeprazole 20 mg should not be exceeded.
Esomeprazols farmakokinetik er undersøgt i doser op til 40 mg to gange dagligt. 
The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d.
Lægemidler, der vides at inducere CYP2C19 eller CYP3A4 eller begge (såsom rifampicin og perikum (Hypericum perforatum)), kan medføre lavere serumniveauer af esomeprazol ved at øge metaboliseringen af esomeprazol. 
Medicinal products known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John's wort (Hypericum perforatum)) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.
Fem dages oral dosering med 20 mg henholdsvis 40 mg esomeprazol opretholdt mavesækkens pH på 4 i en periode på gennemsnitlig 13 henholdsvis 17 timer hos patienter med 24 timers symptomatisk gastroøsofageal reflukssygdom (GERD). 
After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic gastroesophageal reflux disease (GERD) patients.
Lægemidler, der metaboliseres via CYP2C19 
Medicinal products metabolised by CYP2C19
Investigatorerne påviste også, at esomeprazol var signifikant mere effektivt end placebo til lindring af sure opstød (58,5 - 63,6 % versus placebo 28,3 - 37,4 %) under evalueringen i uge 2. 
The investigators also found esomeprazole to be significantly more effective than placebo in resolving acid regurgitation (58.5% - 63.6% vs placebo 28.3% - 37.4%) during the week 2 evaluation.
Luftveje, thorax og mediastinum bronchospasmer 
Respiratory, thoracic and mediastinal disorders bronchospasm
- Øvrige indholdsstoffer: glycerolmonostearat 40-55, hydroxypropylcellulose, hypromellose, magnesiumstearat, methacrylsyre-ethylacrylatcopolymer (1:1) opløsning 30 %, polysorbat 80, sukkerkugler (saccharose og majsstivelse), talcum, triethylcitrat, carmin (E120), indigocarmin (E132), titandioxid (E171), gul jernoxid (E172), erythrosin (E127), allura red AC (E129), povidon K-17, propylenglycol, shellac, natriumhydroxid og gelatine (se afsnit 2, “Nexium Control indeholder saccharose”). 
• The other ingredients are: glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, magnesium stearate, methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30 per cent, polysorbate 80, sugar spheres (sucrose and maize starch), talc, triethyl citrate, carmine (E120), indigo carmine (E132), titanium dioxide (E171), yellow iron oxide (E172), erythrosine (E127), allura red AC (E129), povidone K-17, propylene glycol, shellac, sodium hydroxide, and gelatin (see section 2, “Nexium Control contains sucrose”.)
En anden måde at tage medicinen på 
Alternative method of taking this medicine
De typiske symptomer på refluks er en smertefuld fornemmelse i brystet, som stiger op til halsen (halsbrand) og en sur smag i munden (sure opstød). 
The normal symptoms of reflux are a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Samtidig administration af esomeprazol og atazanavir kan ikke anbefales (se pkt. 
Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5).
Ca. 80 % af nætterne var fri for halsbrand under alle perioder, og 90 % af nætterne var fri for halsbrand i den sidste uge af hvertklinisk studie, sammenlignet med 72,4 - 78,3 % for placebo. 
About 80% of nights were heartburn free during all time periods and 90% of nights were heartburn free by week 2 of each clinical study, compared to 72.4 - 78.3% for placebo.
Du må ikke bruge denne medicin under amning. 
You should not use this medicine during breast-feeding.
Hvis du har glemt at tage Nexium Control 
If you forget to take Nexium Control
Det kan være nødvendigt for din læge at holde øje med dig, når du starter og stopper med at tage Nexium Control. 
Your doctor may need to monitor you when you start or stop taking Nexium Control.
Dette lægemiddel anvendes til voksne til kortvarig behandling af reflukssymptomer (f.eks. halsbrand og sure opstød). 
This medicine is used in adults for the short-term treatment of reflux symptoms (for example, heartburn and acid regurgitation).
I begge studier var esomeprazol 20 mg betydeligt bedre, sammenlignet med placebo, til opnåelse af det primære mål, fuldstændigt ophør af halsbrand defineret som ingen halsbrand i de seneste 7 dage før det sidste besøg (33,9 - 41,6 % versus placebo 11,9 - 13,7 % (p<0,001). 
In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 - 13.7%, (p<0.001).
Hos raske forsøgspersoner medførte samtidig administration af cisaprid og 40 mg esomeprazol en stigning på 32 % i arealet under plasmakoncentrationstidskurven (AUC) og en forlængelse af eliminationshalveringstiden (t½) på 31 %, men der sås ingen signifikant stigning i cisaprids peak-plasmaniveau. 
In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life(t1/2) but no significant increase in peak plasma levels of cisapride.
Hjælpestoffer, som behandleren skal være opmærksom på: Hver hård enterokapsel indeholder 11,5 mg saccharose. 
Excipient(s) with known effect Each gastro-resistant hard capsule contains 11.5 mg sucrose.
- Øvrige indholdsstoffer: glycerolmonostearat 40-55, hydroxypropylcellulose, hypromellose, rødbrun jernoxid (E172), gul jernoxid (E172), magnesiumstearat, methacrylsyre-ethylacrylatcopolymer (1:1) opløsning 30 %, mikrokrystallinsk cellulose, syntetisk paraffin, macrogol 6000, polysorbat 80, crospovidon (Type A), natriumstearylfumarat, sukkerkugler (saccharose og majsstivelse), talcum, titandioxid (E171) og triethylcitrat (se punkt 2, ”Nexium Control indeholder saccharose”). 
- The other ingredients are glycerol monostearate 40-55, hydroxypropylcellulose, hypromellose, reddish-brown iron oxide (E172), yellow iron oxide (E172), magnesium stearate, methacrylic acid ethylacrylate copolymer (1:1) dispersion 30 per cent, cellulose microcrystalline, synthetic paraffin, macrogol 6000, polysorbate 80, crospovidone (Type A), sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E171) and triethyl citrate (see section 2, “Nexium Control contains sucrose”).
Dette skyldes, at kapslen indeholder overtrukne pellets, der sørger for, at medicinen ikke nedbrydes af din mavesyre. 
This is because the capsule contains coated pellets, which stop the medicine from being broken down by the acid in your stomach.
I en undersøgelse med raske forsøgspersoner, var der en mindsket eksponering på næsten 40 % af den aktive metabolit af clopidogrel, når der blev givet en fast dosiskombination med esomeprazol 20 mg + acetylsalicylsyre 81 mg samtidigt med clopidogrel, sammenlignet med clopidogrel alene. 
In a study in healthy subjects, there was a decreased exposure by almost 40% of the active metabolite of clopidogrel when a fixed dose combination of esomeprazole 20 mg + acetylsalicylic acid 81 mg was given with clopidogrel compared to clopidogrel alone.
Det kan være nødvendigt for din læge at holde øje med dig, når du starter og stopper med at tage Nexium Control 
Your doctor may need to monitor you when you start or stop taking Nexium Control
Refluks er tilbageløb af syre fra maven, som stiger op i spiserøret, der kan blive betændt og gøre ondt. 
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”) which may become inflamed and painful.
Brug af anden medicin sammen med Nexium Control 
Other medicines and Nexium Control
• Øget svedtendens 
• Increased sweating.
• Digoxin (anvendes mod hjerteproblemer) 
• Digoxin (used for heart problems)
Behandling med protonpumpehæmmere (PPI) kan forårsage en let forøget risiko for gastrointestinale infektioner såsom Salmonella og Campylobacter, og hos patienter, som er indlagt på hospitalet, muligvis også Clostridium difficile (se pkt. 
Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile (see section 5.1).
Andre lægemidlers virkninger på esomeprazols farmakokinetik Lægemidler, der hæmmer CYP2C19 og/eller CYP3A4 
Effects of other medicinal products on the pharmacokinetics of esomeprazole Medicinal products which inhibit CYP2C19 and/or CYP3A4
• Udvikling af bryster hos mænd 
• Enlarged breasts in men
Må ikke anvendes ved allergi over for esomeprazol eller et af de øvrige indholdsstoffer i denne medicin. 
Do not use if you are allergic to esomeprazole or any of the other ingredients of this medicine.
• Digoxin (anvendes mod hjerteproblemer). 
• Digoxin (used for heart problems).
• Cilostazol (anvendes til behandling af claudicatio intermittens - en tilstand, hvor ringe blodtilførsel til benmuskler forårsager smerter og vanskeligheder med at gå). 
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking).
Natriumhydroxid Titandioxid (E171) 
Sodium hydroxide Titanium dioxide (E171)
• de tidligere har haft mavesår eller har fået foretaget mave-tarm kirurgiske indgreb 
• You have had a stomach ulcer or stomach surgery in the past.
Dette skyldes, at tabletten indeholder overtrukne pellets, der sørger for, at medicinen ikke nedbrydes af din mavesyre. 
This is because the tablet contains coated pellets, which stop the medicine from being broken down by the acid in your stomach.
Hos patienter med svær insufficiens bør en dosis på maksimalt 20 mg derfor ikke overskrides. 
Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction.
Nexium Control indeholder saccharose 
Nexium Control contains sucrose
• Cilostazol (anvendes til behandling af claudicatio intermittens - en tilstand, hvor ringe blodtilførsel til benmuskler forårsager smerter og vanskeligheder med at gå) 
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking)
Efter samlet evaluering af behandlingen af patienter i uge 2 rapporterede 78,0 - 80,7 % af patienterne i esomeprazol 20 mg-gruppen sammenlignet med 72,4 - 78,3 % i placebogruppen, at deres tilstand var forbedret. 
Following Overall Treatment Evaluation (OTE) of patients at week 2, 78.0 - 80.7% of patients on esomeprazole 20 mg, compared to 72.4 - 78.3% for placebo, reported their condition as improved.
Nexium Control er indiceret til kortvarig behandling af reflukssymptomer (f.eks. halsbrand og sure opstød) hos voksne. 
Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.
• de er ældre end 55 år og har nye symptomer eller symptomer, som har ændret sig i den seneste tid 
• They are aged over 55 years with new or recently changed symptoms.
• Påvirkning af mave eller tarm: diarré, mavesmerter, forstoppelse, luft i maven 
• Effects on your stomach or gut: diarrhoea, stomach ache, constipation, wind (flatulence).
• Vorinazol (anvendes til behandling af svampeinfektion) og clarithromycin (anvendes til behandling af infektioner). 
• Voriconazole (used to treat infections caused by a fungus) and clarithromycin (used to treat infections).
Behandling med esomeprazol 20 mg én gang dagligt havde ingen effekt på eksponeringen af amprenavir (med og uden samtidig administration af ritonavir). 
Treatment with esomeprazole 20 mg once a day had no effect on the exposure of amprenavir (with and without concomitant ritonavir).
Esomeprazol hæmmer CYP2C19, det vigtigste enzym i metaboliseringen af esomeprazol. 
Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme.
Samtidig administration af esomeprazol og en kombineret inhibitor af CYP2C19 og CYP3A4 kan resultere i mere end en fordobling af esomeprazoleksponeringen. 
Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure.
Almene symptomer og reaktioner på administrationsstedet utilpashed, øget svedtendens 
General disorders and administration site disorders malaise, increased sweating
Samtidig administration af omeprazol (20 mg én gang dagligt) og atazanavir 400 mg/ritonavir 100 mg til raske frivillige resulterede i et fald i eksponeringen af atazanavir på ca. 30 % sammenlignet med den observerede eksponering med atazanavir 300 mg/ritonavir 100 mg én gang dagligt uden omeprazol 20 mg én gang dagligt. 
The co-administration of omeprazole (20 mg once a day) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg once a day without omeprazole 20 mg once a day.
MÆRKNING DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING
Det kan være nødvendigt at tage kapslerne i 2-3 på hinanden følgende dage for at opnå en forbedring af symptomerne. 
It might be necessary to take the capsules for 2-3 consecutive days to achieve improvement of symptoms.
• Rør rundt, indtil tabletten går i opløsning (blandingen vil ikke være gennemsigtig). 
• Stir until the tablet breaks up (the mixture will not be clear) then drink the mixture straight away or within 30 minutes.
Brug ikke dette lægemiddel efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP.
• Pludseligt åndedrætsbesvær, hævelse af læber, tunge og svælg, udslæt, besvimelse eller synkebesvær (alvorlig allergisk reaktion, der ses sjældent) 
• Sudden wheezing, swelling of your lips, tongue and throat, rash, fainting, or difficulties in swallowing (severe allergic reaction, seen rarely).
Kapslerne må ikke tygges, knuses eller åbnes. 
The capsules must not be chewed, crushed or opened.
• Udslæt, eventuelt med ledsmerter 
• Rash, possibly with pain in the joints.
Omeprazol givet i 40 mg doser til raske forsøgspersoner, viste i et crossover-forsøg øget Cmax og AUC for cilostazol på hhv. 18 % og 26 % og øgning af den aktive metabolit med hhv. 29 % og 69 %. 
Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.
Lægemidler, der inducerer CYP2C19 og/eller CYP3A4 
Medicinal products which induce CYP2C19 and/or CYP3A4
• Tacrolimus (anvendes ved organtransplantation). 
• Tacrolimus (in cases of organ transplantation).
Bivirkninger såsom svimmelhed og synsforstyrrelser er ikke almindelige (se pkt. 
Adverse reactions such as dizziness and visual disturbances are uncommon (see section 4.8).
• Tacrolimus (anvendes ved organtransplantation) 
• Tacrolimus (in cases of organ transplantation)
• hvis du tager en medicin, der indeholder nelfinavir (bruges til behandling af hiv-infektion) 
• If you are taking a medicine containing nelfinavir (used to treat HIV infection).
Pakningsstørrelser 7 og 14 enterotabletter. 
Pack sizes of 7 and 14 gastro-resistant tablets.
Samtidig administration af omeprazol (40 mg én gang dagligt) reducerede gennemsnitlig nelfinavir AUC, Cmax og Cmin med 36-39 %, og gennemsnitlig AUC, Cmax og Cmin for den farmakologisk aktive metabolit M8 blev reduceret med 75-92 %. 
Co-administration of omeprazole (40 mg once a day) reduced mean nelfinavir AUC, Cmax and Cmin by 36-39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%.
Refluks kan give symptomer såsom en smertefuld fornemmelse i brystet, som stiger op til halsen (halsbrand) og en sur smag i munden (sure opstød). 
This may cause you symptoms such as a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Dosering Den anbefalede dosis er 20 mg esomeprazol (1 tablet) pr. dag. 
Posology The recommended dose is 20 mg esomeprazole (one tablet) per day.
Esomeprazol metaboliseres af CYP2C19 og CYP3A4. 
Esomeprazole is metabolised by CYP2C19 and CYP3A4.
Dette kan forårsage svaghed, blå mærker eller en øget modtagelighed over for infektioner 
This can cause weakness, bruising, or make infections more likely.
• Diazepam (anvendes til behandling af angst, muskelafslappende eller mod epilepsi). 
• Diazepam (used to treat anxiety, relax muscles or in epilepsy).
Bånd 
Band
Det sekundære mål, fuldstændigt ophør af halsbrand, defineret som ingen halsbrand på patientens dagbogskort i 7 på hinanden følgende dage, var statistisk signifikant både i uge 1 (10,0 - 15,2 % versus placebo 0,9 - 2,4 %; p = 0,014 henholdsvis p<0,001 i de 2 studier) og i uge 2 (25,2 - 35,7 % versus placebo 3,4 - 9,0 %, p<0,001). 
The secondary endpoint of complete resolution of heartburn, defined as no heartburn on the patient's diary card for 7 consecutive days, was statistically significant at both week 1 (10.0% - 15.2% vs placebo 0.9% - 2.4%, p = 0.014, p<0.001) and week 2 (25.2% - 35.7% vs placebo 3.4% - 9.0%, p<0.001).
Interaktion mellem omeprazol og nogle proteasehæmmere har været rapporteret. 
Omeprazole has been reported to interact with some protease inhibitors.
Dette skyldes, at Nexium Control kan påvirke virkningen af nogle typer medicin, og nogle typer medicin kan påvirke virkningen af Nexium Control. 
This is because this medicine can affect the way some medicines work and some medicines can have an effect on it.
Nervesystemet hovedpine svimmelhed, paræstesi, søvnighed smagsforstyrrelser 
Nervous system disorders headache dizziness, paraesthesia, somnolence taste disturbance
Der er ikke udført forsøg med patienter med nedsat nyrefunktion. 
No studies have been performed in patients with decreased renal function.
• Diazepam (anvendes til behandling af angst, muskelafslappende eller mod epilepsi) 
• Diazepam (used to treat anxiety, relax muscles or in epilepsy)
Bivirkninger såsom svimmelhed og synsforstyrrelser kan forekomme, men er ikke almindelige bivirkninger (se pkt. 
However, side effects such as dizziness and visual disturbances may uncommonly occur (see section 4).
Dosering Den anbefalede dosis er 20 mg esomeprazol (1 kapsel) pr. dag. 
Posology The recommended dose is 20 mg esomeprazole (one capsule) per day.
Pellets må ikke tygges eller knuses. 
The pellets should not be chewed or crushed.
Behandling med omeprazol 20 mg én gang dagligt havde ingen effekt på eksponeringen af darunavir (ved samtidig administration af ritonavir) og amprenavir (ved samtidig administration af ritonavir). 
Treatment with omeprazole 20 mg once a day had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir).